KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Operating Leases (2022 - 2025)

Globus Medical (GMED) has disclosed Operating Leases for 4 consecutive years, with $103.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 24.32% year-over-year to $103.9 million, compared with a TTM value of $103.9 million through Dec 2025, up 24.32%, and an annual FY2025 reading of $103.9 million, up 24.32% over the prior year.
  • Operating Leases was $103.9 million for Q4 2025 at Globus Medical, up from $81.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $103.9 million in Q4 2025 and bottomed at $3.5 million in Q4 2022.
  • Average Operating Leases over 4 years is $75.0 million, with a median of $85.0 million recorded in 2024.
  • The sharpest move saw Operating Leases surged 2519.77% in 2023, then fell 8.18% in 2024.
  • Year by year, Operating Leases stood at $3.5 million in 2022, then soared by 2519.77% to $91.0 million in 2023, then dropped by 8.18% to $83.6 million in 2024, then rose by 24.32% to $103.9 million in 2025.
  • Business Quant data shows Operating Leases for GMED at $103.9 million in Q4 2025, $81.7 million in Q1 2025, and $83.6 million in Q4 2024.